Author

Atsushi Tanaka

Immunology Frontier Research Center, Osaka University - Cited by 5,259 - Immunology

Biography

Dr. Atsushi Tanaka is from Department of Cardiovascular Medicine, Wakayama Medical University, Kimiidera, Wakayama, located in Japan. His study is about Optical Coherence Tomography Analysis of Clinical and Subclinical Plaque Rupture. He is also specialized in Cardiology, Acute coronary syndrome, Electrical & Electronics Engineering, Power Electronics, Electrical Power Engineering and Cardiovascular Medicine. He published 93 articles in good journal and the articles are informative and got good citations.
Title
Cited by
Year
Regulatory T cells in cancer immunotherapy
A Tanaka, S SakaguchiCell research 27 (1), 109-118, 2017201
1242
2017
T cell receptor stimulation-induced epigenetic changes and Foxp3 expression are independent and complementary events required for Treg cell development
N Ohkura, M Hamaguchi, H Morikawa, K Sugimura, A Tanaka, Y Ito, ...Immunity 37 (5), 785-799, 2012201
735
2012
PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
T Kamada, Y Togashi, C Tay, D Ha, A Sasaki, Y Nakamura, E Sato, ...Proceedings of the National Academy of Sciences 116 (20), 9999-10008, 2019201
643
2019
Regulatory T cells and human disease
S Sakaguchi, N Mikami, JB Wing, A Tanaka, K Ichiyama, N OhkuraAnnual Review of Immunology 38, 541-566, 2020202
502
2020
Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)
JD Leverson, H Zhang, J Chen, SK Tahir, DC Phillips, J Xue, P Nimmer, ...Cell death & disease 6 (1), e1590-e1590, 2015201
451
2015
Human FOXP3+ regulatory T cell heterogeneity and function in autoimmunity and cancer
JB Wing, A Tanaka, S SakaguchiImmunity 50 (2), 302-316, 2019201
436
2019
Targeting Treg cells in cancer immunotherapy
A Tanaka, S SakaguchiEuropean journal of immunology 49 (8), 1140-1146, 2019201
265
2019
Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti–CTLA-4 antibody
D Ha, A Tanaka, T Kibayashi, A Tanemura, D Sugiyama, JB Wing, EL Lim, ...Proceedings of the National Academy of Sciences 116 (2), 609-618, 2019201
146
2019
Autoimmune Th17 cells induced synovial stromal and innate lymphoid cell secretion of the cytokine GM-CSF to initiate and augment autoimmune arthritis
K Hirota, M Hashimoto, Y Ito, M Matsuura, H Ito, M Tanaka, H Watanabe, ...Immunity 48 (6), 1220-1232. e5, 2018201
143
2018
Somatic hypermutation and class switch recombination in Msh6−/− Ung−/− double-knockout mice
HM Shen, A Tanaka, G Bozek, D Nicolae, U StorbThe Journal of Immunology 177 (8), 5386-5392, 2006200
134
2006
Graded attenuation of TCR signaling elicits distinct autoimmune diseases by altering thymic T cell selection and regulatory T cell function
S Tanaka, S Maeda, M Hashimoto, C Fujimori, Y Ito, S Teradaira, K Hirota, ...The Journal of Immunology 185 (4), 2295-2305, 2010201
109
2010
Detection of T cell responses to a ubiquitous cellular protein in autoimmune disease
Y Ito, M Hashimoto, K Hirota, N Ohkura, H Morikawa, H Nishikawa, ...Science 346 (6207), 363-368, 2014201
86
2014
The very 5′ end and the constant region of Ig genes are spared from somatic mutation because AID does not access these regions
S Longerich, A Tanaka, G Bozek, D Nicolae, U StorbThe Journal of experimental medicine 202 (10), 1443-1454, 2005200
68
2005
Attracting AID to targets of somatic hypermutation
A Tanaka, HM Shen, S Ratnam, P Kodgire, U StorbJournal of Experimental Medicine 207 (2), 405-415, 2010201
64
2010
Regulatory T cell-specific epigenomic region variants are a key determinant of susceptibility to common autoimmune diseases
N Ohkura, Y Yasumizu, Y Kitagawa, A Tanaka, Y Nakamura, D Motooka, ...Immunity 52 (6), 1119-1132. e4, 2020202
63
2020
Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells
A Tanaka, H Nishikawa, S Noguchi, D Sugiyama, H Morikawa, ...Journal of Experimental Medicine 217 (2), 2020202
59
2020
CCR8-targeted specific depletion of clonally expanded Treg cells in tumor tissues evokes potent tumor immunity with long-lasting memory
Y Kidani, W Nogami, Y Yasumizu, A Kawashima, A Tanaka, Y Sonoda, ...Proceedings of the National Academy of Sciences 119 (7), e2114282119, 2022202
35
2022
Targeting of AID to immunoglobulin genes
U Storb, HM Shen, S Longerich, S Ratnam, A Tanaka, G Bozek, ...Mechanisms of Lymphocyte Activation and Immune Regulation XI: B Cell Biology …, 2007200
19
2007
Thymus, innate immunity and autoimmune arthritis: interplay of gene and environment
S Sakaguchi, S Tanaka, A Tanaka, Y Ito, S Maeda, N Sakaguchi, ...Febs Letters 585 (23), 3633-3639, 2011201
18
2011
PGE2-EP2/EP4 signaling elicits immunosuppression by driving the mregDC-Treg axis in inflammatory tumor microenvironment
D Thumkeo, S Punyawatthananukool, S Prasongtanakij, R Matsuura, ...Cell Reports 39 (10), 1109, 2022202
14
2022

Referred From: https://scholar.google.com/citations?user=lWL8KLsAAAAJ&hl=en&oi=ao

Cited by
Citations 5259
h-index 18
i10-index 20
Recommended Journals
Open Access Journals